Global Information
회사소개 | 문의 | 비교리스트

백반증 : 파이프라인 리뷰

Vitiligo - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 213131
페이지 정보 영문 144 Pages
가격
US $ 2,000 ₩ 2,390,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,781,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,172,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


백반증 : 파이프라인 리뷰 Vitiligo - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 144 Pages

백반증이란 피부의 멜라닌 색소(피부·모발·눈의 색을 결정짓는 색소)가 결핍되는 질환입니다. 주요 증상으로 새치(소년· 청년기에 두발·눈썹·속눈썹·수염이 백색·회색으로 변화), 구강 내부 조직의 탈색, 망막의 탈색·변색 등을 들 수 있습니다. 주요 치료법에는 코르티코스테로이드 요법 및 면역 조정제, 외과 수술등이 있습니다.

세계 각국에서의 백반증 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계의 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

백반증 개요

치료제 개발

  • 파이프라인 제품의 개요
  • 파이프라인 제품 : 기업별
  • 기업에서 개발중인 제품

백반증 : 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

백반증 치료제 개발에 참여하고 있는 기업

  • Aclaris Therapeutics Inc
  • Arrien Pharmaceuticals LLC
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Clinuvel Pharmaceuticals Ltd
  • Incyte Corp

약제 개요

백반증 : 휴지중인 프로젝트

백반증 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.11.02

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Vitiligo, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Vitiligo - Pipeline by 2A Pharma AB, H1 2020
  • Vitiligo - Pipeline by Aclaris Therapeutics Inc, H1 2020
  • Vitiligo - Pipeline by Amgen Inc, H1 2020
  • Vitiligo - Pipeline by AnTolRx Inc, H1 2020
  • Vitiligo - Pipeline by Arrien Pharmaceuticals LLC, H1 2020
  • Vitiligo - Pipeline by Boston Pharmaceuticals Inc, H1 2020
  • Vitiligo - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Vitiligo - Pipeline by Castle Creek Biosciences Inc, H1 2020
  • Vitiligo - Pipeline by Clinuvel Pharmaceuticals Ltd, H1 2020
  • Vitiligo - Pipeline by Incyte Corp, H1 2020
  • Vitiligo - Pipeline by Innovision Therapeutics Inc, H1 2020
  • Vitiligo - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
  • Vitiligo - Pipeline by JN Biosciences LLC, H1 2020
  • Vitiligo - Pipeline by Pfizer Inc, H1 2020
  • Vitiligo - Pipeline by Portola Pharmaceuticals Inc, H1 2020
  • Vitiligo - Pipeline by Radikal Therapeutics Inc, H1 2020
  • Vitiligo - Pipeline by Rheos Medicines Inc, H1 2020
  • Vitiligo - Pipeline by Temprian Therapeutics Inc, H1 2020
  • Vitiligo - Pipeline by Villaris Therapeutics Inc, H1 2020
  • Vitiligo - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Vitiligo, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Pipeline Review, H1 2020, provides an overview of the Vitiligo (Dermatology) pipeline landscape.

Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 9 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Vitiligo - Overview
  • Vitiligo - Therapeutics Development
  • Vitiligo - Therapeutics Assessment
  • Vitiligo - Companies Involved in Therapeutics Development
  • Vitiligo - Drug Profiles
  • Vitiligo - Dormant Projects
  • Vitiligo - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q